Valuation: Clinuvel Pharmaceuticals Limited

Market Cap 507M 355M 312M 290M 266M 500M 34.16B 3.44B 1.34B 16.8B 1.33B 1.3B 58.07B P/E 2026 *
14.2x
P/E 2027 * 13.4x
Enterprise Value 255M 178M 156M 145M 133M 251M 17.15B 1.73B 675M 8.43B 669M 654M 29.15B EV / Sales 2026 *
2.57x
EV / Sales 2027 * 2.13x
Free-Float
83.79%
Yield 2026 *
0.61%
Yield 2027 * 0.8%
1 day-4.69%
3 months-2.71%
6 months-26.86%
Current year-20.78%
Current year 6.1
Extreme 6.1
8.45
1 year 6.1
Extreme 6.1
8.6
3 years 6.1
Extreme 6.1
12.68
5 years 6.1
Extreme 6.1
30.9
10 years 3.78
Extreme 3.78
30.9
Manager TitleAgeSince
Chief Executive Officer 63 01/11/2005
Director of Finance/CFO 42 30/06/2024
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member - 29/01/2018
Director/Board Member - 23/09/2019
Chairman - 01/01/2024
Change 5-day change 1-year change 3-year change Capi.($)
-4.69%-.--% - - 355M
+0.63%-3.06%+16.50%-10.12% 66.74B
+1.23%+2.80%+38.09%+200.66% 53.32B
+10.08%+51.80%+51.80%+51.80% 48.12B
-1.32%-7.38%-57.37%-56.96% 38.25B
+0.78%-1.84%+53.73%-25.20% 29.85B
+0.84%+0.36%+67.62%+84.46% 23.51B
-5.17%-12.54%+58.33%-55.63% 21.45B
-1.21%+1.12%+0.90%+164.17% 19.97B
+1.31%+3.24%+81.47%+157.97% 16.47B
Average +0.25%-0.53%+34.56%+56.79% 35.3B
Weighted average by Cap. +1.48%+0.11%+29.07%+51.17%

Financials

2026 *2027 *
Net sales 99.16M 69.34M 60.9M 56.64M 51.97M 97.66M 6.68B 673M 263M 3.28B 260M 255M 11.35B 105M 73.27M 64.35M 59.84M 54.91M 103M 7.06B 711M 278M 3.47B 275M 269M 11.99B
Net income 35.75M 25M 21.96M 20.42M 18.74M 35.21M 2.41B 242M 94.74M 1.18B 93.85M 91.83M 4.09B 37.77M 26.41M 23.2M 21.57M 19.8M 37.19M 2.54B 256M 100M 1.25B 99.14M 97.01M 4.32B
Net Debt -253M -177M -155M -144M -132M -249M -17.01B -1.71B -669M -8.36B -663M -649M -28.92B -285M -199M -175M -163M -149M -280M -19.16B -1.93B -754M -9.42B -747M -731M -32.57B
Logo Clinuvel Pharmaceuticals Limited
Clinuvel Pharmaceuticals Limited is a specialty pharmaceutical company. It is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the United States of America, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). It has operations in Europe, Singapore, and the United States of America. It develops and manufactures NEURACTHEL (adrenocorticotropic hormone) in different formulations, to target neurological, endocrinological, and degenerative disorders. Its pharmaceutical product, PRENUMBRA, has been developed, and its use is to be expanded in the clinic from stroke to Parkinson's.
Employees
16
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
10.06AUD
Average target price
23.14AUD
Spread / Average Target
+130.03%

Quarterly revenue - Rate of surprise